EP3784355A1 - Composition d'écran solaire - Google Patents

Composition d'écran solaire

Info

Publication number
EP3784355A1
EP3784355A1 EP19716447.8A EP19716447A EP3784355A1 EP 3784355 A1 EP3784355 A1 EP 3784355A1 EP 19716447 A EP19716447 A EP 19716447A EP 3784355 A1 EP3784355 A1 EP 3784355A1
Authority
EP
European Patent Office
Prior art keywords
resorcinol
composition
sunscreen
sunscreen composition
per
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19716447.8A
Other languages
German (de)
English (en)
Inventor
Rajkumar PERUMAL
Ashish Anant Vaidya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Unilever Global IP Ltd
Unilever IP Holdings BV
Original Assignee
Unilever PLC
Unilever NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unilever PLC, Unilever NV filed Critical Unilever PLC
Publication of EP3784355A1 publication Critical patent/EP3784355A1/fr
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34Alcohols
    • A61K8/347Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35Ketones, e.g. benzophenone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59Mixtures
    • A61K2800/591Mixtures of compounds not provided for by any of the codes A61K2800/592 - A61K2800/596
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59Mixtures
    • A61K2800/596Mixtures of surface active compounds

Definitions

  • the present invention relates to a sunscreen composition.
  • the present invention relates to a sunscreen composition that provides improved ultraviolet (UV) A protection factor (UVAPF).
  • UV ultraviolet
  • UVAPF ultraviolet A protection factor
  • Specific skin related issues that people are concerned about include healthy and infection-free skin, good skin tone, adequate moisturization and protection from UV radiation contained in the sunlight.
  • Sunlight comprises infrared region (700 nm to 1 mm), visible region (380 to 780 nm) and UV region (100 to 400 nm).
  • the UV region is composed of UVC (100 to 280 nm), UVB (280 to 315 nm) and UVA (315 to 400 nm). While the human body needs some UV radiation for synthesis / maintenance of adequate amount of vitamin D, harmful effects of UV typically outweighs the benefits.
  • An excessive exposure to UVB is said to cause direct damage to DNA and cause sunburn too; and an excessive exposure to UVA is said to give rise to
  • UVA is also said to cause DNA damages via oxidation reactions that involve reactive oxygen species (Zhang et al., 1997, Free Radical Biology & Medicine, 23, 980- 985).
  • sunscreen composition that offer at least some protection against unwanted effects caused by excessive exposure to UV radiations contained in sunlight.
  • sunscreen compositions comprise sunscreens that absorb UV radiations and prevent them from reaching a surface e.g. skin of a user on which the composition is applied.
  • Organic sunscreens e.g. 4-tert-butyl-4’-methoxydibenzoylmethane (BMDM) absorb the UVA radiation.
  • BMDM 4-tert-butyl-4’-methoxydibenzoylmethane
  • UVAPF sun protection factor
  • organic sunscreens e.g. 2-ethylhexyl 2-cyano- 3,3-diphenylacrylate (OCR) and octyl methoxycinnamate (MCX) absorb the UVB radiation.
  • OCR 2-ethylhexyl 2-cyano- 3,3-diphenylacrylate
  • MCX octyl methoxycinnamate
  • EP 2 431 021 discloses a high SPF sunscreen composition comprising less than 8% total organic sunscreens comprising
  • compositions disclosed therein aim at providing a SPF higher than 15 without compromising on the desired skin sensorial properties.
  • WO 03/ 080009 discloses cosmetic compositions comprising organic sunscreens along with a 4-substituted resorcinol derivatives in a cosmetically acceptable base. The compositions exhibit improved storage stability and oxidative stability.
  • WO 03/080009 particularly discloses a combination of butylmethoxy dibenzoylmethane, octyl methoxycinnamate, stearic acid and 4- substituted resorcinol.
  • WO 11/ 147738 (Unilever) relates to sunscreen compositions that provide SPF (equal to or greater than 15) and high UVAPF (equal to or higher than 4).
  • WO 11/ 147738 discloses a solid sunscreen composition comprising butylmethoxy dibenzoylmethane, a nonionic surfactant of select class, a polymer of select class in a cosmetically acceptable base. WO 11/ 147738 further discloses a non-solid sunscreen composition comprising dibenzoylmethane or its derivative, a nonionic surfactant of select class, a fatty acid and a cosmetically acceptable base.
  • WO 16/ 142129 (Unilever) discloses a combination of C12-C20 fatty acid with C12-C20 fatty acid soap, white pigment e.g. titanium dioxide in a cosmetically acceptable carrier wherein the mole ratio of soap to fatty acid is from 0.23 to 0.5. WO 16/142129 solves the problem of providing photoprotection whilst maintaining the sensorial properties of the compositions when pigments like titanium dioxide are added to fatty acid containing compositions.
  • compositions that provide improved UVAPF remains a topic of interest. Need therefore exists to develop a sunscreen composition that provides improved UVAPF.
  • composition comprising a compound selected from resorcinol, phenylethyl resorcinol, 4-alkyl substituted resorcinol and mixtures thereof along with UVA organic sunscreen, UVB organic sunscreen of select class, fatty acid and soap, provides improved UVAPF.
  • the present invention relates to a sunscreen composition
  • a sunscreen composition comprising:
  • the present invention relates to a method of providing improved UVAPF, the method comprising applying on the skin a sunscreen composition of the first aspect and optionally, rinsing with water.
  • the present invention relates to use of the composition of the first aspect for providing improved UVAPF. Detailed description of the invention
  • the present invention relates to a sunscreen composition
  • a sunscreen composition comprising:
  • UVA organic sunscreen a. 0.1 to 5 wt% UVA organic sunscreen
  • b 0.1 to 10 wt% 2-ethylhexyl 2-cyano-3,3-diphenylacrylate, c. 0.1 to 2.5 wt% of a compound selected from resorcinol, phenylethyl resorcinol, 4-alkyl substituted resorcinol and mixtures thereof,
  • UVA organic sunscreen e. 0.1 to 10 wt% soap.
  • composition according to the present invention comprises UVA organic sunscreen that absorbs UVA radiations and prevents them from reaching a surface e.g. skin of a user.
  • sunscreen that may be used as UVA organic sunscreen is selected from a dibenzoylmethane compound, diethylamino hydroxybenzoyl hexyl benzoate, and mixtures thereof.
  • sunscreen that may be used as UVA organic sunscreen is selected from BMDM (commercially available as Parsol® 1789 or Avobenzone) 2-methyldibenzoylmethane, 4-isopropyldibenzoyl-methane, 4-tert- butyldibenzoylmethane, 2,4-dimethyldibenzoylmethane, 2,5- dimethyldibenzoylmethane, 4,4'-diisopropyl-dibenzoylmethane, 2-methyl-5- isopropyl-4'-methoxydibenzoylmethane, 2-methyl-5-tert-butyl-4'-methoxy- dibenzoyl methane, 2,4-dimethyl-4'-methoxy dibenzoylmethane, 2,6-dimethyl- 4-tert-butyl-4'-methoxy-dibenzoylmethane and mixtures thereof.
  • BMDM commercially available as Parsol® 1789 or A
  • sunscreen that may be used as UVA organic sunscreen is BMDM.
  • the composition comprises 0.1 to 5 wt%, preferably 0.5 to 4.5 wt%, more preferably 1 to 4 wt%, even more preferably 1 to 3.5 wt%, further more preferably 1 to 3 wt%, still more preferably 1 to 2.5 wt% of one or more UVA organic sunscreens.
  • the composition comprises OCR (commercially available as OctocryleneTM) that absorbs UVB radiation and prevents them from reaching a surface e.g. skin.
  • OCR commercially available as OctocryleneTM
  • the composition comprises 0.1 to 10 wt%, preferably 0.5 to 9 wt%, more preferably 1 to 8 wt%, even more preferably 1.5 to 7 wt%, further more preferably 2 to 6 wt%, still more preferably 2.5 to 5 wt% and most preferably 3 to 4 wt% OCR.
  • Resorcinol phenylethyl resorcinol (PER), 4-alkyl substituted resorcinol
  • the composition comprises a compound selected from resorcinol, PER, 4-alkyl substituted resorcinol and mixtures thereof.
  • a compound selected from resorcinol, PER, 4-alkyl substituted resorcinol and mixtures thereof are known to provide skin lightening effect.
  • the compound selected is 4-alkyl substituted resorcinol.
  • the alkyl group in 4-alkyl substituted resorcinol can be straight chain alkyl or branched chain alkyl.
  • the alkyl group can be straight chain alkyl as in the case of 4-propyl resorcinol or it can be a branched chain alkyl like as in the case of 4-isopropyl resorcinol (IPR).
  • 4-alkyl substituted resorcinol examples include 4-methyl resorcinol, 4-ethyl resorcinol (ER), 4-propyl resorcinol, IPR, 4-butyl resorcinol (BR), 4-pentyl resorcinol, 4-hexyl resorcinol (HR), 4-heptyl resorcinol, 4-octyl resorcinol and mixtures thereof.
  • Preferred 4-alkyl substituted resorcinol are ER, BR, HR and mixtures thereof. More preferred 4-alkyl substituted resorcinol are ER, HR and mixtures thereof.
  • the composition may comprise a combination of one or more compounds selected from resorcinol, PER and 4-alkyl substituted resorcinol.
  • the composition may comprise one or more 4-alkyl substituted resorcinol in presence or absence of resorcinol.
  • the composition comprises one compound selected from resorcinol, PER, 4-alkyl substituted resorcinol.
  • the composition comprises 0.1 to 2.5 wt%, preferably 0.1 to 2.25 wt%, more preferably 0.25 to 2 wt%, even more preferably 0.25 to 1.5 wt%, further more preferably 0.25 to 1 wt%, still more preferably 0.25 to 0.75 wt% and most preferably 0.25 to 0.5 wt% resorcinol, PER, 4-alkyl substituted resorcinol and mixtures thereof.
  • the composition comprises fatty acid. Fatty acids when present in a
  • compositions along with a soap provide the so called vanishing cream effect, i.e. a composition, when applied on to the human skin, vanishes on the skin leaving behind no significant streaks of the composition.
  • the composition comprises fatty acids having carbon atoms preferably in the range 10 to 22, more preferably 12 to 22, even more preferably 14 to 22, further more preferably 16 to 22, yet more preferably from 18 to 22. It is found that a fatty acid with increasing chain length provides increasing UVAPF and/or increasing SPF.
  • fatty acids that may be used in the composition include lauric, myristic, palmitic, stearic, isostearic, oleic, linoleic, arachidic, behenic, erucic acid and mixtures thereof.
  • the fatty acid that may preferably be used is stearic acid or palmitic acid or a mixture thereof.
  • the fatty acid in the present invention is preferably hystric acid which is substantially (generally about 90 to 95%) a mixture of stearic acid and palmitic acid in a ratio of between 55:45 to 45:55.
  • the composition comprises 4 to 25 wt%, preferably 6 to 22 wt%, more preferably 8 to 20 wt%, even more preferably 10 to 19 wt% and further more preferably 12 to 18 wt% fatty acid.
  • the composition comprises soap. Soap when present in combination with fatty acid in the composition provides the so called vanishing effect.
  • Soap of the invention is generally prepared by in-situ neutralization of fatty acid present in the composition.
  • the soap has a carbon chain length that corresponds to the chain length of fatty acid in the
  • the soap is formed from the fatty acid through use of alkali metal hydroxides e.g. sodium hydroxide or potassium hydroxide. Of the two, potassium hydroxide is more preferred.
  • the soap is preferably a potassium soap (potassium salt of fatty acid).
  • the composition comprises 0.1 to 10 wt%, preferably 1 to 8 wt%, more preferably 2 to 7 wt%, even more preferably 2 to 6 wt%, further more preferably 2 to 5 wt% and most preferably 2 to 4 wt% soap.
  • the composition further comprises a nonionic surfactant having HLB value in the range 9 to 20, preferably 10 to 19, more preferably 12 to 18, even more preferably 13 to 17 and yet more preferably 15 to 17.
  • a nonionic surfactant having HLB value in the range 9 to 20, preferably 10 to 19, more preferably 12 to 18, even more preferably 13 to 17 and yet more preferably 15 to 17.
  • HLB 20 x Mh / M wherein Mh is the molecular mass of the hydrophilic portion of the molecule and M is the molecular mass of the whole molecule, giving a result on an arbitrary scale of 0 to 20.
  • Typical values for various surfactants are given below:
  • a value from 4 to 8 indicates an anti-foaming agent
  • a value from 7 to 11 indicates a W/O (water in oil) emulsifier
  • a value from 12 to 16 indicates oil in water emulsifier
  • a value from 11 to 14 indicates a wetting agent
  • a value from 12 to 15 is typical of detergents
  • a value of 16 to 20 indicates a solubiliser or a hydrotrope.
  • the nonionic surfactant having HLB value in the range 9 to 20 is selected from fatty alcohol ethoxylates, alkyl phenol ethoxylates,
  • nonionic surfactants are ones with at least 9 alkylene oxide groups preferably at least 9 ethylene oxide groups.
  • Brij ® 35 polyoxyethylene (20) cetyl ether
  • HLB polyoxyethylene (20) cetyl ether
  • HLB polyethylene glycol octadecyl ether
  • TritonTM X705 commercially available as TritonTM X705.
  • the nonionic surfactant having HLB value in the range 9 to 20 that may be present in the composition is fatty alcohol ethoxylate with saturated carbon chain having HLB higher than 15.5.
  • the composition comprises 0.5 to 5 wt%, more preferably 1 to 4 wt%, even more preferably from 2 to 3 wt% nonionic surfactant having HLB in the range 9 to 20.
  • the composition further comprises a polymer. The polymer acts as thickener in the composition and improves sensorial properties of the composition.
  • the polymer is preferably selected from the following classes:
  • methacrylate crosspolymer (commercially available as AculynTM 88),
  • - acrylate/R-alkyl acrylate crosspolymer e.g. acrylates/C10-C30 alkyl acrylate crosspolymer (commercially available as PemulenTM TR-2),
  • methyacrylate e.g. Ammonium acryloyldimethyltaurate/ beheneth-25 methacrylate crosspolymer (commercially available as Aristoflex ® HMB and Aristoflex ® BLV); and mixtures thereof.
  • the polymer is selected from acrylate / R-methacrylate copolymer, acrylates copolymer and mixtures thereof.
  • the composition comprises 0.1 to 5 wt%, more preferably 0.5 to 4.5 wt%, even more preferably 1 to 4 wt%, further more preferably from 1.5 to 3.5 wt%, still more preferably from 2 to 3 wt% polymer.
  • the composition comprises a cosmetically acceptable vehicle that includes water and may be present in the composition in amount 5 to 99.9 wt%, preferably 10 to 95 wt%, more preferably 15 to 90 wt%, even more preferably 20 to 80 wt%, further more preferably 25 to 75 wt% and still more preferably 30 to 70 wt%.
  • the composition further comprises one or more skin lightening agents.
  • skin lightening agents may be selected from niacinamide, vitamin B6, vitamin C, vitamin A, glutathione precursors, galardin, adapalene, aloe extract, ammonium lactate, arbutin, azelaic acid, butyl hydroxy anisole, butyl hydroxy toluene, citrate esters, deoxyarbutin, 1 ,3-diphenyl propane derivatives, 2,5-dihydroxybenzoic acid and its derivatives, 2-(4- acetoxyphenyl)-1 ,3-dithiane, 2-(4-hydroxyphenyl)-1 ,3-dithiane, ellagic acid, gluco pyranosyl-1 -ascorbate, gluconic acid, glycolic acid, green tea extract, 4- Hydroxy-5-methyl-3[2H]-furanone, 4-hydroxyanisole and its derivatives, 4- hydroxybenzoic acid derivative
  • 12-hydroxystearic acid When used in the composition, 12-hydroxystearic acid is used as a skin lightening agent and not as a fatty acid.
  • skin lightening agents that may be used in the composition are niacinamide, vitamin B6, 12-hydroxystearic acid, glutathione precursors, galardin and mixtures thereof.
  • a skin lightening agent When incorporated in the composition, a skin lightening agent may be added in an amount 0.001 to 15 wt%, preferably 0.01 to 10 wt%, more preferably 0.1 to 5 wt%, even more preferably 0.5 to 3 wt%, in the composition.
  • the composition further comprises emollients.
  • emollients examples include stearyl alcohol, glyceryl monoricinoleate, mink oil, cetyl alcohol, isopropyl isostearate, isobutyl palmitate, isocetyl stearate, oleyl alcohol, isopropyl laurate, hexyl laurate, decyl oleate, octadecan-2-ol, isocetyl alcohol, eicosanyl alcohol, behenyl alcohol, cetyl palmitate, silicone oils such as dimethylpolysiloxane, din-butyl sebacate, isopropyl myristate, isopropyl palmitate, isopropyl stearate, butyl stearate, polyethylene glycol, triethylene glycol, lanolin, cocoa butter, corn oil, cotton seed oil, olive oil, palm kernel oil, rape seed oil, safflower seed oil, evening primrose oil, soybean oil,
  • the composition further comprises solvents.
  • solvents that may be used in the composition include ethyl alcohol, isopropanol, acetone, ethylene glycol monoethyl ether, diethylene glycol monobutyl ether, diethylene glycol monoethyl ether and mixtures thereof.
  • the composition further comprises powders.
  • powders that may be used in the composition include chalk, talc, fullers earth, kaolin, starch, gums, colloidal silica sodium polyacrylate, tetra alkyl and/or trialkyl aryl ammonium smectites, chemically modified magnesium aluminium silicate, organically modified montmorillonite clay, hydrated aluminium silicate, fumed silica, carboxyvinyl polymer, sodium carboxymethyl cellulose, ethylene glycol monostearate and mixtures thereof.
  • the composition further comprises preservatives to protect against the growth of potentially harmful microorganisms.
  • preservatives examples include alkyl esters of para-hydroxybenzoic acid, hydantoin derivatives, propionate salts, and a variety of quaternary ammonium compounds.
  • ingredients that may be used as preservative in the composition are sodium benzoate, iodopropynyl butyl carbamate, methylisothiazolinone, iodopropynylbutylcarbamate, phenoxyethanol, methyl paraben, propyl paraben, imidazolidinyl urea, sodium dehydroacetate, ethylhexylglycerin, benzyl alcohol, alkane diols and mixtures thereof.
  • the alkane diols that are suitable for use as preservative are C6-C12 alkanes that are vicinally substituted with hydroxy groups.
  • Illustrative examples include 1 ,2- octane diol (caprylyl glycol), 2,3-octane diol, 1 ,2-nonane diol, 1 ,2-decane diol, 1 ,2-hexane diol, 3,4-octane diol, mixtures thereof or the like where caprylyl glycol is typically the most preferred.
  • preservatives are added preferably in an amount 0.001 to 5 wt%, more preferably 0.01 to 3 wt% and most preferably 0.02 to 2 wt%.
  • composition may further comprise a range of other optional ingredients that include antioxidants, binders, biological additives, buffering agents, colorants, astringents, fragrance, opacifying agents, conditioners, exfoliating agents, pH adjusters, skin soothing agents, and skin healing agents.
  • composition is preferably formulated in the form of a powder, flake, lotion, cream, gel or mousse. More preferably, the composition is formulated in the form of cream or lotion and most preferably in the form of cream.
  • composition can be a leave-on or wash-off type of composition.
  • composition is preferably a leave-on type of composition.
  • the packaging for the composition of this invention can be a patch, bottle, tube, roll-ball applicator, propellant driven aerosol device, squeeze container or lidded jar.
  • a resorcinol, phenylethyl resorcinol, 4-alkyl substituted resorcinol and mixtures thereof improve the UVAPF when present in the composition according to the first aspect. It is also found that such improved UVAPF is obtained only when OCR was used in presence of UVA organic sunscreen. An improved UVAPF was not obtained when other UVB organic sunscreen e.g. MCX was used instead of OCR. OCR is known to stabilize dibenzoylmethane compound, e.g. BMDM.
  • UVAPF improvement in UVAPF obtained in presence of a compound selected from resorcinol, phenylethyl resorcinol, 4- alkyl substituted resorcinol and mixtures thereof, is over and above the UVAPF obtained when OCR is used instead of MCX in the same composition.
  • a compound selected from resorcinol, phenylethyl resorcinol, 4- alkyl substituted resorcinol and mixtures thereof is over and above the UVAPF obtained when OCR is used instead of MCX in the same composition.
  • the sunscreen composition is a composition comprising:
  • the sunscreen composition is a composition comprising:
  • the present invention further relates to a method of providing improved UVAPF, wherein the method comprises the step of:
  • the present invention also provides a method of providing improved UVAPF comprising the steps of applying the composition of the first aspect on to a surface e.g. skin, in case of a leave-on composition.
  • This method optionally comprises an additional step of at least partially removing the composition from the surface if it is in the form of a wash-off composition.
  • the method is non-therapeutic or cosmetic.
  • the present invention relates to use of the composition of the first aspect for improved UVAPF.
  • the composition as per the present invention was prepared as follows: Demineralised water and potassium hydroxide were charged in a beaker (main beaker) mounted on a magnetic stirrer and heater. The water phase was heated to 75 ° C and maintained at the same temperature. In a side pot, a fatty acid mentioned in examples below was heated to 75 ° C for melting and was added to the main beaker maintained at 75 ° C. The system was stirred for 5 minutes at 75°C. The sunscreens as mentioned in examples, other oil soluble ingredients and nonionic surfactant were taken in a separate beaker and heated to 65 to 70°C for melting. They were mixed well and were added to the main beaker. Stirring was continued for another 5 minutes at 75 ° C. The stirrer and heater were switched off and mixing was done manually until temperature reached ambient (25°C). Measurement of In-vitro SPF / UVA-PF
  • Thin film transmittance measurements were done using SPF-290S SPF meter (Optometries Corporation). In this study, 70 x 70 mm PMMA plate with 6 pm roughness from Schonberg GmbFI & Co were used. The percent transmittance of the various compositions was measured as follows. 2 mg/cm 2 of a test sample was applied on PMMA plate, distributed uniformly using a syringe, and spread uniformly. The drying time for the PMMA plates was 30 minutes. After the drying time, sample plates were exposed to UV light and transmittance scan was recorded. This scan gives the transmittance as a function of wavelength (290 to 400 nm) for a given sample. For a single plate, six to eight different spots were scanned. The same was repeated for 3 plates.
  • the data reported is thus an average over 18 readings.
  • the reference transmittance scan was obtained using a blank plate, with no sample on the PMMA plates with glycerin spread on it.
  • the transmittance values were used to arrive at the SPF values using the Win SPF software provided with the instrument.
  • the transmittance values used to calculate the UVAPF values for each composition.
  • compositions outlined in examples shown in Table 1 were tested in a randomized human volunteer study carried out with appropriate controls. Briefly, minimum erythemal dose (MED) and minimal persistent pigment darkening dose (MPPDD) for each volunteer was estimated before sample (compositions in table 1 ) application. The test samples were blinded with the standard samples for which the SPF/UVAPF is known. The required amount of sample (2 mg/cm 2 ) was applied on the back skin of volunteers. The samples were dispensed uniformly using a syringe and applied uniformly using a finger cot over a period of 20 to 50 seconds which depends on the ease of application of a composition. For each sample new finger cot is used. Post sample application, the subjects were exposed to UV, dosage of which is calculated based on MED and MPPDD (specific to each volunteer) and on the anticipated or target
  • the data in table 1 shows that improved UVAPF is obtained using compositions as per the present invention (examples 1 and 2) that comprises FIR along with BMDM, OCR, fatty acid and soap as compared to the comparative examples (example A and B; not as per the present invention) that do not contain FIR. Further, the data also shows that improved UVAPF is obtained only when a select UVB sunscreen, i.e. OCR (example 1 ), is used instead of MCX (example C) despite that both these compositions comprise the same amount, i.e. 0.5 wt%, of FIR.
  • FIR provided improved UVAPF when used in combination with UVA organic sunscreen, 2-ethylhexyl 2-cyano-3,3-diphenylacrylate, fatty acid and soap. This improved UVAPF was not obtained when MCX was present instead of OCR.
  • compositions of example B and C has no effect on UVAPF.
  • compositions outlined in table 2 demonstrate the effect of presence of soap in the composition as compared to the control (no soap).
  • the data in table 2 shows that soap, when present in the composition as per the present invention, boosts SPF as well as UVAPF. Further, additional compositions as shown in table 3 below were prepared as described earlier and UVAPF and SPF were measured as described earlier.
  • the data in table 3 shows that an enhanced UVAPF is obtained when palmitic acid as shown in example 6; or stearic acid as shown in example 7, were used in the composition.
  • the data in table 3 also shows that an enhanced UVAPF is obtained when BR as shown in example 8; or ER as shown in example 9, were used in the composition.
  • the sunscreen compositions as per the present invention provide an improved UVAPF.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne une composition d'écran solaire. En particulier, la composition d'écran solaire comprend la fourniture d'un facteur amélioré de protection contre les ultraviolets A (UVAPF). La composition comprend un écran solaire organique contre les UVA, du 2-cyano-3,3-diphénylacrylate de 2-éthylhexyle, un composé choisi parmi le résorcinol, le phényléthylrésorcinol, le résorcinol substitué par un alkyle en position 4 et des mélanges de ceux-ci, un acide gras et un savon.
EP19716447.8A 2018-04-23 2019-04-15 Composition d'écran solaire Pending EP3784355A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18168640 2018-04-23
PCT/EP2019/059662 WO2019206714A1 (fr) 2018-04-23 2019-04-15 Composition d'écran solaire

Publications (1)

Publication Number Publication Date
EP3784355A1 true EP3784355A1 (fr) 2021-03-03

Family

ID=62046690

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19716447.8A Pending EP3784355A1 (fr) 2018-04-23 2019-04-15 Composition d'écran solaire

Country Status (9)

Country Link
EP (1) EP3784355A1 (fr)
JP (1) JP7362641B2 (fr)
CN (1) CN112004579A (fr)
CA (1) CA3095273A1 (fr)
EA (1) EA202092522A1 (fr)
MX (1) MX2020011125A (fr)
PH (1) PH12020551441A1 (fr)
WO (1) WO2019206714A1 (fr)
ZA (1) ZA202005699B (fr)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6869598B2 (en) * 2002-03-22 2005-03-22 Unilever Home & Personal Care Usa Division Of Conopco, Inc. Stabilization of sunscreens in cosmetic compositions
JP4691464B2 (ja) * 2006-03-28 2011-06-01 株式会社資生堂 皮膚用又は毛髪用組成物
US20130189204A1 (en) 2010-05-25 2013-07-25 Charu Duggal Sunscreen composition
EP2431021A1 (fr) * 2010-09-16 2012-03-21 Unilever N.V. Composition d'écran solaire
CA2813094C (fr) * 2010-10-12 2018-07-03 Unilever Plc Composition d'ecran solaire
EP2789369B1 (fr) * 2013-04-14 2018-06-06 Symrise AG Une composition pour éclaircissement de peau et de cheveu
EP3267968A2 (fr) * 2015-03-10 2018-01-17 Unilever NV Composition d'hygiène personnelle

Also Published As

Publication number Publication date
JP7362641B2 (ja) 2023-10-17
KR20210005561A (ko) 2021-01-14
CA3095273A1 (fr) 2019-10-31
EA202092522A1 (ru) 2021-02-11
WO2019206714A1 (fr) 2019-10-31
CN112004579A (zh) 2020-11-27
MX2020011125A (es) 2020-11-11
JP2021519277A (ja) 2021-08-10
PH12020551441A1 (en) 2021-08-23
ZA202005699B (en) 2022-09-28

Similar Documents

Publication Publication Date Title
US20210106509A1 (en) A sunscreen composition
AU2007287653B2 (en) Photostable cosmetic compositions
BR112021007957B1 (pt) Mistura líquida e transparente de filtros uv, composição cosmética, dermatológica ou farmacêutica e uso da mistura ou composição
EP2771072B1 (fr) Composition photo-protectrice aqueuse de soins personnels
JP2006016400A (ja) 安息香酸アリールアルキル誘導体によってジベンゾイルメタン誘導体を光安定化させる方法、および光防護用化粧品組成物
US20130266527A1 (en) High spf sunscreen composition
WO2020030396A1 (fr) Composition topique
CA2788030C (fr) Composition d'ecran solaire photostable
BR112015017297B1 (pt) Composição cosmética ou dermatológica e processos cosméticos não terapêuticos
KR102722050B1 (ko) 선스크린 조성물
EP3784355A1 (fr) Composition d'écran solaire
US20170007519A1 (en) Sunscreen composition
EA046155B1 (ru) Солнцезащитная композиция
CA2510305C (fr) Procede de photostabilisation d'un derive de dibenzoylmethane par un derive arylalkyl benzoate et une huile amidee; compositions cosmetiques photoprotectrices
WO2021234005A1 (fr) Composition de soins personnels
WO2021249760A1 (fr) Composition cosmétique comprenant du 6-méthyl-picolinamide

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20201020

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: UNILEVER IP HOLDINGS B.V.

Owner name: UNILEVER GLOBAL IP LIMITED

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: UNILEVER IP HOLDINGS B.V.

Owner name: UNILEVER GLOBAL IP LIMITED

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230425